Who qualifies

Low-T Ads: Care and Claim Checks

Concerned about a Low-T ad and later treatment? Save the actual ad, prescription and care dates.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202610 sources

This may apply to you if

  • Gather product names, prescriptions and dates you can confirm.
  • Keep diagnosis, treatment and authorized medical records.
  • Ask which proof, legal rules and personal time limit apply.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

U.S. Department of Health and Human Services · Publisher of the June 2026 FDA request announcement

Finding: FDA requested further revisions to age-related and prostate labeling information in June 2026. The announcement describes requested changes, not completed revisions to every product label.

HHS requested testosterone label updates (opens in a new tab) · Jun 18, 2026 · Checked Oct 4, 2026

The evidence and its limits

Cleveland Clinic and collaborating institutions; funded by AbbVie and others · New England Journal of Medicine · 2023

TRAVERSE cardiovascular safety trial

Design:
Randomized controlled trial
Participants:
5,246 men aged 45–80 with low testosterone symptoms and preexisting or high cardiovascular risk; randomized to daily 1.62% skin gel or placebo.
Finding:
Major cardiac events met the prespecified noninferiority criterion; atrial fibrillation, acute kidney injury and pulmonary embolism occurred more often in the testosterone group.
Main limitation
Specific male population and gel regimen; mean follow-up 33 months. Not zero-risk or lifetime safety evidence, and not proof of the cause of one person’s injury.

Read the source: TRAVERSE cardiovascular safety trial (opens in a new tab) · Checked Oct 4, 2026

U.S. Food and Drug Administration · 2025

FDA required blood-pressure monitoring study review

Design:
Agency review
Participants:
Review of required product-specific ambulatory blood-pressure studies; no single participant count supplied in the announcement.
Finding:
Completed studies showed increased blood pressure across testosterone products.
Main limitation
Agency summary of monitoring studies, not the TRAVERSE randomized enrollment or proof of one person’s injury cause.

Read the source: FDA required blood-pressure monitoring study review (opens in a new tab) · Checked Oct 4, 2026

The short answer

Who may have a marketing-related claim to check?
Ask about the actual message, product use and harm. Keep what you received with its date. A broad Low-T slogan does not establish a personal claim. [6]
What does not qualify as proof that an ad was false?
A symptom checklist or later warning is not a fraud finding. A prescription does not decide cause. The legal question needs the actual statement and context. [1]
What if my treatment was for aging or another medical issue?
Ask the clinician to explain the diagnosis and reason for treatment. Do not self-diagnose from an ad. Have the actual product label checked. [2]
What records help explain the message and treatment?
Save the ad or message you have, with its source and date. Keep prescription and care records. Mark anything recalled without a document. [9]

What rules a case out

Not covered by this case

  • A study or court grouping does not decide a person’s cause, fault or payment.
  • No single national filing deadline is supplied.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

The criteria attorneys check

  1. 01

    Gather product names, prescriptions and dates you can confirm.

  2. 02

    Keep diagnosis, treatment and authorized medical records.

  3. 03

    Ask which proof, legal rules and personal time limit apply.

Concerned about a Low-T ad and later treatment? Save the actual ad, prescription and care dates. A marketing claim is not proven fraud. Ask a clinician about care and a lawyer about the facts.

What does not qualify as proof that an ad was false?

A symptom checklist or later warning is not a fraud finding. A prescription does not decide cause. The legal question needs the actual statement and context.

FDA’s 2025 action changed cardiovascular boxed wording after new trial data and added blood-pressure warnings. In June 2026 the agency requested further age-related and prostate revisions. Those different actions should not be collapsed into a claim that all older marketing was proved true or false.

What if my treatment was for aging or another medical issue?

Ask the clinician to explain the diagnosis and reason for treatment. Do not self-diagnose from an ad. Have the actual product label checked.

FDA’s information page describes medical indications and the later requested age-related update. A request does not show that every product label already changed. The trial studied selected men, so its findings are not a universal guarantee for anyone seeking treatment after an advertisement.

What records help explain the message and treatment?

Save the ad or message you have, with its source and date. Keep prescription and care records. Mark anything recalled without a document.

Do not recreate wording from another advertisement or substitute a company story for the exact product used. Covered health-record access has exceptions and allowed copy fees. Ask counsel which message, diagnosis or treatment gap matters before deciding what sensitive files to send.

Is there a deadline for a marketing claim?

Ask which claim and law set your time limit. There is no national ad cutoff here. A drug notice is not your personal filing date.

The general court explanation says time limits depend on the claim and applicable law. Keep the dates of the message, treatment and injury available for that review. Do not assume that reading a new safety statement restarts a period or that gathering records files a complaint.

What happens when I check a marketing claim?

Ask the lawyer to explain the actual statement being assessed. Confirm representation and the next step. Read fees and expenses in writing.

Ask what costs could remain if unsuccessful and what evidence is still needed. The ABA model rule is not a quote from your provider. Keep medical decisions with your clinician rather than treating a fraud allegation, intake reply or study headline as advice to change treatment.

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Sources

  1. FDA February 2025 testosterone labeling changesFDA February 2025 testosterone labeling changes · regulator
  2. FDA current Testosterone InformationFDA current Testosterone Information · regulator
  3. HHS requested testosterone label updatesHHS requested testosterone label updates · regulator
  4. FORTESTA prescribing information and Medication Guide, July 2025FORTESTA prescribing information and Medication Guide, July 2025 · regulator
  5. Lincoff and colleagues: Cardiovascular Safety of Testosterone-Replacement TherapyLincoff and colleagues: Cardiovascular Safety of Testosterone-Replacement Therapy · study
  6. JPML initial testosterone products transfer orderJPML initial testosterone products transfer order · court
  7. Testosterone Topical: MedlinePlus Drug InformationTestosterone Topical: MedlinePlus Drug Information · regulator
  8. ABA Model Rule 1.5 feesABA Model Rule 1.5 fees
  9. HHS your medical recordsHHS your medical records · regulator
  10. SDNY how long do I have to file?SDNY how long do I have to file? · court

Checked against 10 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026